DBV Technologies
Clinical-stage biopharmaceutical company developing epicutaneous immunotherapy (EPIT) treatments for food allergies, including the Viaskin platform for peanut allergy.
Notes
DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Bagneux, France, with operations in the United States. The company pioneered epicutaneous immunotherapy (EPIT) delivered through Viaskin, a proprietary patch technology designed to activate the immune system through the skin.
The company's lead product candidate, Viaskin Peanut, is being developed for the treatment of peanut allergy in children. DBV Technologies has been working towards FDA approval for Viaskin Peanut, which would represent a novel approach to treating food allergies through a non-invasive patch delivery system.
DBV Technologies is publicly traded on Euronext Paris (DBV) and NASDAQ (DBVT), having gone public in 2014.
Team
- Daniel Tassé - Chief Executive Officer
- Sébastien Robitaille - Chief Financial Officer
- Pharis Mohideen, M.D. - Chief Medical Officer
- Hugh Sampson, M.D. - Co-founder & Chief Scientific Advisor
Additional Research Findings
- Founded in 2002 in France
- Publicly traded: Euronext Paris (DBV) and NASDAQ (DBVT)
- IPO in 2014
- Headquarters in Bagneux, Île-de-France, France
- US operations in Montrouge and Summit, New Jersey
- 101-250 employees
- Viaskin platform uses epicutaneous immunotherapy (EPIT)
- Lead candidate: Viaskin Peanut for peanut allergy in children
- Portfolio company of Sofinnova Partners
- Technology activates immune system through intact skin
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |